Finerenone vs. Placebo in addition to Standard of Care on the Progression of Kidney Disease in non-Diabetic Patients
Trial to examine: -the impact of Finerenone vs. Placebo in delaying the progression of kidney disease. -the safety of Finerenone vs. Placebo in addition to standard of care treatment -quality of life measures via survey This trial will include 1580 participants worldwide. Study duration is approximately 2.5-4 years with an estimated 18 visits. Procedures include blood and urine collection, vital signs, EKG, questionnaires, and phone calls in between visits. The study offers an option for some visits to occur remotely. Compensation for participation is provided.
-Age 18 years and older -Chronic kidney disease -Proteinuria -Non-diabetic Exclusion criteria: -Polycystic kidney disease -Organ transplant recipient -Uncontrolled blood pressure Further eligibility will be assessed by study coordinator.
Principal Investigator